ABCL
Price
$2.84
Change
+$0.13 (+4.80%)
Updated
Dec 20, 04:59 PM (EDT)
66 days until earnings call
FATE
Price
$1.69
Change
+$0.03 (+1.81%)
Updated
Dec 20, 04:59 PM (EDT)
72 days until earnings call
Ad is loading...

ABCL vs FATE

Header iconABCL vs FATE Comparison
Open Charts ABCL vs FATEBanner chart's image
AbCellera Biologics
Price$2.84
Change+$0.13 (+4.80%)
Volume$39.24K
CapitalizationN/A
Fate Therapeutics
Price$1.69
Change+$0.03 (+1.81%)
Volume$97.27K
CapitalizationN/A
ABCL vs FATE Comparison Chart
Loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABCL vs. FATE commentary
Dec 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and FATE is a Hold.

COMPARISON
Comparison
Dec 21, 2024
Stock price -- (ABCL: $2.84 vs. FATE: $1.69)
Brand notoriety: ABCL and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 83% vs. FATE: 307%
Market capitalization -- ABCL: $838.84M vs. FATE: $192.48M
ABCL [@Biotechnology] is valued at $838.84M. FATE’s [@Biotechnology] market capitalization is $192.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, ABCL is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 5 TA indicator(s) are bullish while FATE’s TA Score has 3 bullish TA indicator(s).

  • ABCL’s TA Score: 5 bullish, 3 bearish.
  • FATE’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ABCL is a better buy in the short-term than FATE.

Price Growth

ABCL (@Biotechnology) experienced а +1.07% price change this week, while FATE (@Biotechnology) price change was -7.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

ABCL is expected to report earnings on Feb 25, 2025.

FATE is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($839M) has a higher market cap than FATE($192M). ABCL YTD gains are higher at: -50.263 vs. FATE (-54.813). FATE has higher annual earnings (EBITDA): -177.57M vs. ABCL (-202.4M). ABCL has more cash in the bank: 643M vs. FATE (297M). ABCL has less debt than FATE: ABCL (71.4M) vs FATE (99M). ABCL has higher revenues than FATE: ABCL (33M) vs FATE (13.4M).
ABCLFATEABCL / FATE
Capitalization839M192M437%
EBITDA-202.4M-177.57M114%
Gain YTD-50.263-54.81392%
P/E RatioN/AN/A-
Revenue33M13.4M246%
Total Cash643M297M216%
Total Debt71.4M99M72%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
74
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
94
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABCLFATE
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 13 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
66%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTZFX51.590.81
+1.60%
FullerThaler Behvrll Uncnstd Eq R6
ODICX44.190.36
+0.82%
Invesco Discovery C
SROIX12.700.09
+0.71%
Calamos Antetokounmpo Sustainable Eqs I
CSMCX46.890.25
+0.54%
Congress Small Cap Growth Institutional
FCENX11.64N/A
N/A
Franklin International Core Equity Adv

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with VCYT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+4.80%
VCYT - ABCL
56%
Loosely correlated
+4.66%
BEAM - ABCL
54%
Loosely correlated
+8.16%
PRME - ABCL
54%
Loosely correlated
+4.66%
DNA - ABCL
53%
Loosely correlated
+15.33%
AURA - ABCL
53%
Loosely correlated
+1.23%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+1.81%
ALLO - FATE
58%
Loosely correlated
+1.63%
RCKT - FATE
51%
Loosely correlated
+2.03%
PIRS - FATE
51%
Loosely correlated
N/A
CRBU - FATE
51%
Loosely correlated
-0.83%
CCCC - FATE
50%
Loosely correlated
+2.60%
More